Omega Therapeutics offers a proprietary epigenomic programming platform.
Omega Therapeutics has raised $40.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2023.
Omega Therapeutics's investors include HarbourVest Partners, BlackRock, Point72, Fidelity, Flagship Pioneering.
Omega Therapeutics is headquartered in Cambridge, United States.
Omega Therapeutics offers a proprietary epigenomic programming platform.
Omega Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Omega Therapeutics — Funding & Investors." VCBacked, February 23, 2023, https://www.vcbacked.co/company/omega-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Omega Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/omega-therapeutics
{{cite web |title=Omega Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/omega-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated